A Phase 1 interventional study of MLN0128 and paclitaxel in Advanced Solid Malignancies and Hematologic Malignancies, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-08.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.
Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 212th largest by enrollment of the 658 interventional ones that give a count, is one of 26 that started in 2011, is one of 195 in phase 1, and was the 180th registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.
Browse Hematologic Neoplasms studies →181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
University of Arizona · Sites in United States
Ages up to 65
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
Orum Therapeutics USA, Inc. · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–110 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
821 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 276 · Phase 2 280 · Phase 3 43 · Phase 4 9
First in 1989; this study’s year is marked. 26 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 40 across the 658 interventional studies, 150 across the 157 observational. Of the 497 that completed or were terminated, 208 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
215 of 821 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 5 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
90 of the studies in Hematologic Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07504458Phase 3Quetzal TherapeuticsPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | 2027-03 |
| NCT04188418Phase 3M.D. Anderson Cancer CenterFentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients | 2027-08-31 |
| NCT02862275National Cancer Institute (NCI)Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | 2026-11-21 |
| NCT05745285University of MiamiLeukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | 2026-11-30 |
| NCT02203903Catherine BollardMulti-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies | 2026-11-30 |
Add all 90 to your calendar (.ics) → With an account.
Among the 821 studies in Hematologic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I, open label, dose escalation study of oral administration of MLN0128 in combination with paclitaxel, with/without trastuzumab, in participants with advanced solid malignancies.
This is a Phase I, open-label study consisting of a dose escalation phase in advanced solid malignancies to determine the maximum tolerated dose (MTD) of oral administration of MLN0128 in 1 or more dosing schedules, combined with paclitaxel on Days 1, 8 and 15 of each cycle, followed by an expansion phase for further safety and preliminary efficacy.
Once the MTD is determined for each of the dosing schedules evaluated, a dose and schedule will be selected for the expansion phase, which may enroll participants into 2 arms in parallel:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MLN0128 and paclitaxel (MLN0128P): MLN0128 30 mg, capsule, orally, once weekly (QW) + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
Drug: MLN0128 · Drug: paclitaxel
MLN0128 40 mg, capsule, orally, once a week (QW) + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
Drug: MLN0128 · Drug: paclitaxel
MLN0128 6 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
Drug: MLN0128 · Drug: paclitaxel
MLN0128 7 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
Drug: MLN0128 · Drug: paclitaxel
MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
Drug: MLN0128 · Drug: paclitaxel
MLN0128 9 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
Drug: MLN0128 · Drug: paclitaxel
MLN0128 10 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
Drug: MLN0128 · Drug: paclitaxel
MLN0128 7 mg, capsule, orally, once daily 5 days on/2 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
Drug: MLN0128 · Drug: paclitaxel
MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in human epidermal growth factor receptor 2 negative (HER-) cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
Drug: MLN0128 · Drug: paclitaxel
MLN0128 + paclitaxel + trastuzumab (MLN0128PH): MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 plus trastuzumab 4 mg/kg loading dose on Day 1 followed by 2 mg/kg, intravenous each week of a 4-week cycle in HER+ cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
Drug: MLN0128 · Drug: paclitaxel · Drug: trastuzumab
MLN0128 capsules
paclitaxel intravenous infusion
trastuzumab intravenous infusion
Dose Escalation Phase: Maximum Tolerated Dose (MTD)
MTD is the highest dose level at which the participants tolerate treatment without dose-limiting toxicities during the first cycle (28 days) of therapy.
Time frame: Cycle 1: Days 1 to 28
Dose Escalation Phase: Number of Participants With at Least 1 Dose Limiting Toxicity (DLT)
DLT was defined as any of the following occurring during Cycle 1 (Days 1-28) and attributable to MLN0128P: Grade ≥ 3 nonhematologic toxicity; Grade 3 thrombocytopenia with hemorrhage; Grade 4 neutropenia lasting \> 7 days in the absence of growth factor support; Grade 4 neutropenia of any duration associated with fever 38.5 degrees C and/or infection; Any other Grade 4 hematologic toxicity; Inability to administer at least 75 % of doses of MLN0128 within Cycle 1 due to drug-related toxicity; Any clinically significant occurrence which the investigators and sponsor agree would place participants at undue safety risk; Participants who experienced an adverse event (AE) that met the definition for a DLT.
Time frame: Cycle 1: Days 1 to 28
Objective Response Rate (ORR)
ORR was defined as the percentage of participants with Complete Response (CR) and Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Each cycle was a 28 day cycle. CR was defined as the disappearance of all target lesions and for non-target lesions, the disappearance of all non-target lesions and normalization of tumor marker level. PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions.
Time frame: At screening and thereafter every 2 cycles of treatment until disease progression (Up to 65.8 weeks)
Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events(SAEs), AEs Resulting in Discontinuation of MLN0128 and Fatal AEs Within 30 Days of Last Dose of Study Drug
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: First dose of study drug through 30 days after the administration of the last dose of study drug (Up to approximately 91.4 weeks)
Cmax: Maximum Observed Plasma Concentration for MLN0128
Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.
Time frame: Cycles 1 and 2: Day 1 or 2
Cmin: Minimum Observed Plasma Concentration for MLN0128
Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.
Time frame: Cycles 1 and 2: Day 1 or 2
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN0128
Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i.e., C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.
Time frame: Cycles 1 and 2: Day 1 or 2
Terminal Phase Elimination Half-life (T1/2) for MLN0128
Time frame: Cycle 1 Day 1
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN0128
Time frame: Cycle 1 Day 1
AUC(0-6): Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours for MLN0128
Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 30 and 40 mg QW arms.
Time frame: Cycles 1 and 2: Day 1 or 2
Cmax: Maximum Observed Plasma Concentration for Paclitaxel
Time frame: Cycles 1 and 2: Day 1
Cmin: Minimum Observed Plasma Concentration for Paclitaxel
Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.
Time frame: Cycles 1 and 2: Day 1 or 2
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Paclitaxel
Time frame: Cycles 1 and 2: Day 1
Terminal Phase Elimination Half-life (T1/2) for Paclitaxel
Time frame: Cycle 1 Day 1
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Paclitaxel
Time frame: Cycle 1 Day 1
AUC(0-6): Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours for Paclitaxel
Time frame: Cycle 1 Day 1
AUC(0-24): Area Under the Plasma Concentration-time Curve Extrapolated to 24 Hours for Paclitaxel
Time frame: Cycle 1 Day 1
CL: Total Clearance Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel
Time frame: Cycle 1 Day 1
Vss: Volume of Distribution at Steady State Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel
Time frame: Cycle 1 Day 1
Participants took part in the study at three investigative sites in the United States from 28 February 2011 to 15 Sep 2017.
| Milestone | MLN0128P 30 or 40 mg QW | MLN0128P 6, 7, 8, 9 or 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW | Expansion Cohort MLN0128P 8 mg QD×3d QW HER2- | Expansion Cohort MLN0128PH 8mg QD×3d QW HER2+ Plus Trastuzumab |
|---|---|---|---|---|---|
| Started | 8 | 29 | 11 | 13 | 7 |
| Treated | 8 | 29 | 10 | 13 | 7 |
| Dose-escalation evaluable | 7 | 23 | 10 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 8 | 29 | 11 | 13 | 7 |
| Withdrew: Disease progression | 5 | 13 | 6 | 8 | 5 |
| Withdrew: Adverse event | 1 | 10 | 1 | 2 | 0 |
| Withdrew: Participant decision | 2 | 6 | 3 | 3 | 2 |
| Withdrew: Enrolled but not treated | 0 | 0 | 1 | 0 | 0 |
MTD is the highest dose level at which the participants tolerate treatment without dose-limiting toxicities during the first cycle (28 days) of therapy.
| mg (QD×3d QW) | Dose Escalation |
|---|---|
| Dose Escalation Phase: Maximum Tolerated Dose (MTD) | 8 |
DLT was defined as any of the following occurring during Cycle 1 (Days 1-28) and attributable to MLN0128P: Grade ≥ 3 nonhematologic toxicity; Grade 3 thrombocytopenia with hemorrhage; Grade 4 neutropenia lasting \> 7 days in the absence of growth factor support; Grade 4 neutropenia of any duration associated with fever 38.5 degrees C and/or infection; Any other Grade 4 hematologic toxicity; Inability to administer at least 75 % of doses of MLN0128 within Cycle 1 due to drug-related toxicity; Any clinically significant occurrence which the investigators and sponsor agree would place participants at undue safety risk; Participants who experienced an adverse event (AE) that met the definition for a DLT.
| participants | MLN0128P 30 mg QW | MLN0128P 40 mg QW | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW | MLN0128P 8 mg QD×3d QW | MLN0128P 9 mg QD×3d QW | MLN0128P 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW |
|---|---|---|---|---|---|---|---|---|
| Dose Escalation Phase: Number of Participants With at Least 1 Dose Limiting Toxicity (DLT) | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 2 |
ORR was defined as the percentage of participants with Complete Response (CR) and Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Each cycle was a 28 day cycle. CR was defined as the disappearance of all target lesions and for non-target lesions, the disappearance of all non-target lesions and normalization of tumor marker level. PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions.
| percentage of participants | MLN0128P 30 or 40 mg QW | MLN0128P 6, 7, 8, 9 or 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW | Expansion Cohort MLN0128P 8 mg QD×3d QW HER2- | Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus Trastuzumab |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 0 | 9 | 44 | 10 | 20 |
Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.
| ng/mL | MLN0128P 30 mg QW | MLN0128P 40 mg QW | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW | MLN0128P 8 mg QD×3d QW | MLN0128P 9 mg QD×3d QW | MLN0128P 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 | 245.0 (136.00 to 456.00) | 345.5 (306.00 to 385.00) | 26.7 (19.10 to 40.30) | 31.1 (20.40 to 52.40) | 41.8 (19.80 to 79.70) | 34.2 (23.90 to 47.10) | 100.0 (57.50 to 162.00) | 53.5 (26.70 to 101.00) |
| Cycle 2 | 242.2 (105.00 to 356.00) | 107.0 (107.00 to 107.00) | 33.8 (14.70 to 58.70) | 45.5 (40.40 to 50.50) | 53.1 (46.00 to 57.20) | 23.0 (10.80 to 36.60) | 80.1 (21.00 to 166.00) | 45.3 (11.60 to 79.50) |
Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.
No measurements were reported for this outcome.
Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i.e., C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.
| hours | MLN0128P 30 mg QW | MLN0128P 40 mg QW | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW | MLN0128P 8 mg QD×3d QW | MLN0128P 9 mg QD×3d QW | MLN0128P 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 | 3.0 (0.50 to 5.92) | 3.0 (2.00 to 4.00) | 2.0 (2.00 to 3.83) | 3.0 (1.03 to 4.08) | 5.6 (1.02 to 5.65) | 4.1 (3.67 to 6.00) | 1.0 (0.53 to 2.17) | 1.6 (0.65 to 5.53) |
| Cycle 2 | 2.0 (1.87 to 3.90) | 4.0 (4.00 to 4.00) | 4.0 (2.00 to 4.02) | 2.0 (1.97 to 2.00) | 1.0 (0.92 to 4.00) | 5.5 (2.00 to 6.00) | 2.0 (1.00 to 5.75) | 2.7 (0.50 to 5.72) |
| hours | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW |
|---|---|---|
| Terminal Phase Elimination Half-life (T1/2) for MLN0128 | 6.6 (6.36 to 6.91) | 7.2 (7.03 to 7.30) |
| ng*hr/mL | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW |
|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN0128 | 206.5 (183.00 to 230.00) | 286.0 (269.00 to 303.00) |
Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 30 and 40 mg QW arms.
| ng*hr/mL | MLN0128P 30 mg QW | MLN0128P 40 mg QW | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW | MLN0128P 8 mg QD×3d QW | MLN0128P 9 mg QD×3d QW | MLN0128P 10 mg QD×3d QW |
|---|---|---|---|---|---|---|---|
| Cycle 1 | 753.7 (428.00 to 1290.00) | 1325.0 (1210.00 to 1440.00) | 104.4 (73.70 to 146.00) | 121.7 (82.70 to 187.00) | 139.9 (58.00 to 282.00) | 146.2 (99.20 to 229.00) | 347.0 (203.00 to 505.00) |
| Cycle 2 | 883.6 (464.00 to 1340.00) | 505.0 (505.00 to 505.00) | 106.8 (55.50 to 165.00) | 174.0 (162.00 to 186.00) | 210.3 (143.00 to 253.00) | 72.6 (28.10 to 144.00) | 283.9 (65.60 to 660.00) |
| ng/mL | MLN0128P 30 mg QW | MLN0128P 40 mg QW | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW | MLN0128P 8 mg QD×3d QW | MLN0128P 9 mg QD×3d QW | MLN0128P 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW |
|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 2538.0 (1090.00 to 3220.00) | 2355.0 (2210.00 to 2500.00) | 1933.3 (1280.00 to 3170.00) | 1942.5 (1540.00 to 2420.00) | 1620.0 (1290.00 to 1990.00) | 3798.3 (1270.00 to 11100.00) | 2906.9 (2090.00 to 4020.00) | 1637.7 (410.00 to 2770.00) |
| Cycle 2, Day 1 | 3462.5 (2300.00 to 4210.00) | 1500.0 (1500.00 to 1500.00) | 1200.3 (421.00 to 2090.00) | 1550.0 (1550.00 to 1550.00) | 3103.3 (1440.00 to 4890.00) | 1602.3 (597.00 to 2350.00) | 2964.0 (1560.00 to 4070.00) | 1765.7 (654.00 to 2670.00) |
Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.
No measurements were reported for this outcome.
| hours | MLN0128P 30 mg QW | MLN0128P 40 mg QW | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW | MLN0128P 8 mg QD×3d QW | MLN0128P 9 mg QD×3d QW | MLN0128P 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW |
|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 1.1 (1.02 to 1.17) | 1.1 (1.03 to 1.17) | 1.1 (1.00 to 1.15) | 1.2 (0.87 to 1.55) | 1.2 (1.08 to 1.62) | 1.1 (1.00 to 2.22) | 1.1 (0.52 to 1.87) | 1.5 (1.00 to 1.88) |
| Cycle 2, Day 1 | 1.1 (1.00 to 1.47) | 1.2 (1.2 to 1.2) | 1.6 (1.0 to 1.6) | 1.4 (1.20 to 1.50) | 1.2 (1.07 to 1.75) | 1.2 (1.08 to 1.83) | 1.0 (0.95 to 1.17) | 1.1 (1.02 to 1.55) |
| hours | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW | MLN0128P 9 mg QD×3d QW | MLN0128P 10 mg QD×3d QW |
|---|---|---|---|---|
| Terminal Phase Elimination Half-life (T1/2) for Paclitaxel | 10.0 (9.93 to 10.00) | 9.1 (8.83 to 9.48) | 9.6 (8.19 to 11.60) | 9.3 (9.10 to 9.53) |
| ng*hr/mL | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW | MLN0128P 9 mg QD×3d QW | MLN0128P 10 mg QD×3d QW |
|---|---|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Paclitaxel | 4590.0 (3440.00 to 5740.00) | 4790.0 (4040.00 to 6270.00) | 5002.0 (2910.00 to 6330.00) | 5485.0 (4550.00 to 6420.00) |
| ng*hr/mL | MLN0128P 30 mg QW | MLN0128P 40 mg QW | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW | MLN0128P 8 mg QD×3d QW | MLN0128P 9 mg QD×3d QW | MLN0128P 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW |
|---|---|---|---|---|---|---|---|---|
| AUC(0-6): Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours for Paclitaxel | 3198.3 (1560.00 to 4140.00) | 3515.0 (2930.00 to 4100.00) | 2620.0 (1800.00 to 3970.00) | 3157.5 (2810.00 to 3550.00) | 2683.3 (1820.00 to 3630.00) | 5315.0 (1880.00 to 15100.00) | 3683.8 (2600.00 to 5330.00) | 2657.0 (1140.00 to 5350.00) |
| ng*hr/mL | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW | MLN0128P 9 mg QD×3d QW | MLN0128P 10 mg QD×3d QW |
|---|---|---|---|---|
| AUC(0-24): Area Under the Plasma Concentration-time Curve Extrapolated to 24 Hours for Paclitaxel | 3583.3 (2510.00 to 5160.00) | 4332.5 (3670.00 to 5510.00) | 6415.0 (2550.00 to 15900.00) | 5135.0 (4290.00 to 5980.00) |
| L/hr | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW | MLN0128P 9 mg QD×3d QW | MLN0128P 10 mg QD×3d QW |
|---|---|---|---|---|
| CL: Total Clearance Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel | 36.2 (24.70 to 47.70) | 34.8 (22.30 to 45.30) | 31.2 (22.30 to 48.20) | 25.8 (19.30 to 32.30) |
| L | MLN0128P 6 mg QD×3d QW | MLN0128P 7 mg QD×3d QW | MLN0128P 9 mg QD×3d QW | MLN0128P 10 mg QD×3d QW |
|---|---|---|---|---|
| Vss: Volume of Distribution at Steady State Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel | 313.5 (189.00 to 438.00) | 262.0 (219.00 to 306.00) | 252.2 (149.00 to 441.00) | 150.0 (120.00 to 180.00) |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| percentage of participants | MLN0128P 30 or 40 mg QW | MLN0128P 6, 7, 8, 9 or 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW | Expansion Cohort MLN0128P 8 mg QD×3d QW HER2- | Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus Trastuzumab |
|---|---|---|---|---|---|
| TEAE | 100 | 100 | 100 | 100 | 100 |
| SAE | 63 | 41 | 60 | 31 | 43 |
| Fatal AEs within 30 Days of Last Dose Study Drug | 25 | 7 | 20 | 15 | 14 |
| AEs Resulting in Discontinuation of MLN0128 | 13 | 34 | 10 | 15 | 0 |
Collected over First dose of study drug through 30 days after the administration of the last dose of study drug (Up to approximately 91.4 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MLN0128P 30 or 40 mg QW | 2/8 (25%) | 5/8 (62.5%) | 8/8 (100%) |
| MLN0128P 6, 7, 8, 9 or 10 mg QD×3d QW | 2/29 (6.9%) | 12/29 (41.4%) | 29/29 (100%) |
| MLN0128P 7 mg QD×5d QW | 2/10 (20%) | 6/10 (60%) | 10/10 (100%) |
| Expansion Cohort MLN0128P 8 mg QD×3d QW HER2- | 2/13 (15.4%) | 4/13 (30.8%) | 13/13 (100%) |
| Expansion Cohort MLN0128PH 8mg QD×3d QW HER2+ Plus Trastuzumab | 1/7 (14.3%) | 3/7 (42.9%) | 7/7 (100%) |
| Event | MLN0128P 30 or 40 mg QW | MLN0128P 6, 7, 8, 9 or 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW | Expansion Cohort MLN0128P 8 mg QD×3d QW HER2- | Expansion Cohort MLN0128PH 8mg QD×3d QW HER2+ Plus Trastuzumab |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/8 | 2/29 | 2/10 | 2/13 | 0/7 |
| Small intestinal obstructionGastrointestinal disorders | 0/8 | 2/29 | 0/10 | 0/13 | 1/7 |
| HaematemesisGastrointestinal disorders | 0/8 | 0/29 | 0/10 | 0/13 | 1/7 |
| GastroenteritisInfections and infestations | 0/8 | 0/29 | 0/10 | 0/13 | 1/7 |
| Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/8 | 0/29 | 0/10 | 0/13 | 1/7 |
| Oesophageal ulcerGastrointestinal disorders | 1/8 | 0/29 | 0/10 | 0/13 | 0/7 |
| VomitingGastrointestinal disorders | 1/8 | 0/29 | 0/10 | 1/13 | 0/7 |
| SepsisInfections and infestations | 1/8 | 1/29 | 0/10 | 0/13 | 0/7 |
| Laryngeal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/8 | 0/29 | 0/10 | 0/13 | 0/7 |
| Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/8 | 1/29 | 0/10 | 0/13 | 0/7 |
| Event | MLN0128P 30 or 40 mg QW | MLN0128P 6, 7, 8, 9 or 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW | Expansion Cohort MLN0128P 8 mg QD×3d QW HER2- | Expansion Cohort MLN0128PH 8mg QD×3d QW HER2+ Plus Trastuzumab |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 4/8 | 18/29 | 6/10 | 6/13 | 6/7 |
| VomitingGastrointestinal disorders | 5/8 | 10/29 | 3/10 | 7/13 | 6/7 |
| FatigueGeneral disorders | 4/8 | 19/29 | 8/10 | 9/13 | 4/7 |
| Decreased appetiteMetabolism and nutrition disorders | 2/8 | 12/29 | 7/10 | 4/13 | 4/7 |
| HyperglycaemiaMetabolism and nutrition disorders | 5/8 | 14/29 | 3/10 | 3/13 | 4/7 |
| DiarrhoeaGastrointestinal disorders | 3/8 | 15/29 | 6/10 | 7/13 | 4/7 |
| AnaemiaBlood and lymphatic system disorders | 4/8 | 12/29 | 3/10 | 4/13 | 2/7 |
| DehydrationMetabolism and nutrition disorders | 4/8 | 12/29 | 2/10 | 3/13 | 1/7 |
| StomatitisGastrointestinal disorders | 2/8 | 13/29 | 4/10 | 5/13 | 3/7 |
| ConstipationGastrointestinal disorders | 3/8 | 4/29 | 2/10 | 1/13 | 3/7 |
All Subjects as Treated (ASaT) population, which consisted of all enrolled participants who received at least 1 dose of MLN0128.
| Age, Continuous(years) | MLN0128P 30 or 40 mg QW | MLN0128P 6, 7, 8, 9 or 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW | Expansion Cohort MLN0128P 8 mg QD×3d QW HER2- | Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus Trastuzumab | Total |
|---|---|---|---|---|---|---|
| Mean | 57.3 ± 14.34 | 62.9 ± 9.57 | 58.1 ± 14.70 | 54.2 ± 14.46 | 58.1 ± 8.03 | 59.3 ± 12.07 |
| Sex: Female, Male(Participants) | MLN0128P 30 or 40 mg QW | MLN0128P 6, 7, 8, 9 or 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW | Expansion Cohort MLN0128P 8 mg QD×3d QW HER2- | Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus Trastuzumab | Total |
|---|---|---|---|---|---|---|
| Female | 5 | 14 | 7 | 6 | 6 | 38 |
| Male | 3 | 15 | 3 | 7 | 1 | 29 |
| Race/Ethnicity, Customized(Participants) | MLN0128P 30 or 40 mg QW | MLN0128P 6, 7, 8, 9 or 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW | Expansion Cohort MLN0128P 8 mg QD×3d QW HER2- | Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus Trastuzumab | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 | 1 | 3 |
| Not Hispanic or Latino | 8 | 28 | 10 | 12 | 6 | 64 |
| Race/Ethnicity, Customized(Participants) | MLN0128P 30 or 40 mg QW | MLN0128P 6, 7, 8, 9 or 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW | Expansion Cohort MLN0128P 8 mg QD×3d QW HER2- | Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus Trastuzumab | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 0 | 1 | 0 | 2 | 0 | 3 |
| White | 8 | 27 | 10 | 10 | 7 | 62 |
| Region of Enrollment(Participants) | MLN0128P 30 or 40 mg QW | MLN0128P 6, 7, 8, 9 or 10 mg QD×3d QW | MLN0128P 7 mg QD×5d QW | Expansion Cohort MLN0128P 8 mg QD×3d QW HER2- | Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus Trastuzumab | Total |
|---|---|---|---|---|---|---|
| United States | 8 | 29 | 10 | 13 | 7 | 67 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Feb 2011 to primary completion in Sep 2017, 78 months.
Results were first posted in Aug 2019, 1 year 10 months after primary completion.
Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's 78 months is above that.
Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sapanisertib · Paclitaxel
Millennium Pharmaceuticals, Inc. →